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ABSTRACT
Objective: To determine whether or not Autologous conditioned IL-1 antagonist (ACS) reduce
pain in patients with OA or lumbar radiculopathy.
Study Design: Review of 3 randomized, double-blind controlled clinical trials in 2007, 2008,
and 2009, all in English.
Data Sources: Two randomized, double-blinded controlled clinical trials comparing the
effectiveness of intraarticular injections of an autologous IL-1 receptor antagonist solution versus
a control in OA and one randomized, double-blinded controlled clinical trials comparing
autologous IL-1 receptor antagonist epidural injection versus 5 and 10 mg triamcinolone in
patients with lumbar radiculopathy.
Outcomes Measured: The outcomes in this study were measured using the Western Ontario and
McMaster Osteoarthritis Index (WOMAC), Knee Injury and Osteoarthritis Outcome Score
(KOOS), Visual Analogue Scale (VAS), and the Oswestry Disability Index (ODI).
Results: Baltzer et al. determined a statistically significant reduction in OA-related pain when
compared to both saline and hyaluronic acid. Yang et al. failed to show pain reduction in ACStreated patients when compared to placebo. Becker et al. reported significant reductions in pain,
but were not statistically significant when compared to the control arm.
Conclusion: Results of the mentioned studies proved that ACS does decrease pain in patients
with OA and LR; however, this pain reduction was not universally statistically significant and
thus requiring further, more uniform trials. The Baltzer et al. results were encouraging, however,
and do warrant future investigation.
Keywords: Orthokine, Interleukin-1 inhibitor, autologous conditioned serum, osteoarthritis.
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Introduction:
Osteoarthritis (OA) – an inflammatory condition of the bone caused by recurrent force
and trauma – and lumbar radiculopathies – excessive radicular pain caused by lumbar disc
degeneration and stenosis – are pervasive, often disabling, and degenerative conditions that lead
to recurrent pain and loss of function. OA and lumbar radiculopathies (LR) affect approximately
27 million people and 1/100 adults in America, respectively.1,2 Even more concerning, the
estimated lifetime risk of developing symptomatic OA in a patient’s lifetime is ~45%.2 OA and
lumbar radiculopathies are degenerative processes that do not resolve, often requiring constant
medical intervention. The average annual disease cost for each OA patient is ~ $5,700 a year,
while the total annual inpatient cost for treating OA reached $48 billion in 2008.2 The average
number of knee replacements per year is estimated to rise 673% from 2004 to 2030, or from
478,000 to 3.48 million, respectively.2
The exact mechanism of both disease processes are well documented and understood. OA
of the knee develops due to a failure in its protective mechanisms, leading to joint injury. More
specifically, constant strenuous force on the joint leads to the wearing down of cartilage, making
the bone susceptible to damage. In response to this damage, the bone becomes sclerotic and
forms osteophytes, which grow through the cartilage and cause increased mechanical friction and
damage. Lumbar radiculopathy, on the other hand, is not a pathology itself, but more a sequelae
of an underlying disorder, those typically being degenerative disc disease or spinal stenosis, both
of which are due to improper body mechanics and persistent degenerative forces.1 Symptoms of
OA include pain localized to the specific joint, pain that worsens with activity and is relieved by
rest, and acute and intermittent flare-ups (especially with humidity). Symptoms for LR include
shooting pain and numbness in the lower back, groin, buttocks, and legs.
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Currently, there are many treatment options for OA, including dietary regimens, wearing
barefoot or minimalist shoes, and pharmacological or surgical interventions.3,4 Common
pharmacological approaches include analgesics (acetaminophen, NSAID’s, or Cox-2 inhibitors),
codeine, topical creams (analgesics or capsaicin), intraarticular injections (corticosteroids,
hyaluronic acid (HA), or platelet-rich plasma (PRP), though none of these treat the underlying
pathology. Surgical options include arthroscopic debridement and total joint replacement. For
lumbar radiculopathies, the available treatments are non-pharmacological (physical therapy,
weight loss, and activity modification), pharmacological (NSAID’s or epidural corticosteroid
injections), and surgical (laminectomy or spinal fusion).
Due to the limited efficacy and adverse effects of current pharmacological approaches,
reluctance to make substantial lifestyle and dietary changes, along with the numerous risks
associated with surgical interventions, patients and researchers are searching for new
pharmaceutical alternatives. Within the past decade, researchers in Germany have developed an
intraarticular injection championed by a litany of professional athletes: Autologous conditioned
serum (ACS). ACS – an autologous conditioned IL-1 receptor antagonist (IL-1Ra) – is produced
by removing blood from a patient, placing the blood in a test tube with glass beads that activate
IL-1Ra leukocytes, and centrifuging the products to isolate the leukocytes.5 The targeting of IL-1
is a novel approach because it is a cytokine known for its pro-inflammatory properties.
Researchers believe that by decreasing IL-1 production, they will be able to inhibit the damage
wrought by inflammation in OA and LR. The purpose of this study is to analyze the utility of
ACS in the treatment of OA and LR.
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Objective:
The objective of this selective EBM review is to determine whether or not “Autologous
conditioned IL-1 antagonist (ACS) reduce pain in patients with OA or lumbar radiculopathy?”

Methods:
The studies in this analysis included 3 double-blinded, RCT’s where the patient
population ranged from 84 to 376 for the Becker et al. (2007) and Baltzer et al. (2009) studies,
respectively. The interventions for the OA studies both included intraarticular injections of an
autologous IL-1 receptor antagonist solution; however, Baltzer et al. included, along with the
control, a comparative arm of HA. The intervention studied by Becker et al. (2007) was an
autologous IL-1 receptor antagonist epidural injection versus 5 and 10 mg triamcinolone as the
controls. The injection schedule was once per week for 3 consecutive weeks in the Baltzer et al.
(2009) and Becker et al. (2007) studies, whereas the Yang et al. (2008) study interventions
occurred on days 0, 3, 7, 10, 14, and 21. Inclusion and exclusion criteria, amongst other study
demographics and characteristics are listed in Table 1 below.6.7.8
Key words used in searches included “Interleukin-1 inhibitor and autologous conditioned
serum” and “Autologous interleukin-1 and osteoarthritis.” All articles were published in English
in peer-reviewed journals. Articles were searched online via PUBMED, OVID, and google and
were selected based on relevance to the clinical intervention being assessed and the inclusion of
patient-oriented outcomes (POEMS). Inclusion criteria for the articles selected included studies
that were randomized, controlled, and double-blinded, whereas exclusion criteria consisted
solely of patients under 18 years of age. The statistics reported in the studies included Chi-square,
p-value, and analysis of variance one-way method (ANOVA).
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Table 1: Demographics and characteristics of patient populations by study
Study
Type
# Pts Age,
Inclusion
Exclusion Criteria
yrs
Criteria
- Grade IV OA
Balzter Double
376
≥30 -Dx w/ primary
OA for at least 3
- Systemic or
et al.
blind
months
inflammatory joint ds
(2009)4
RCT
- Willing to d/c
- Bone CA or mets near
all analgesia and
joint
NSAIDs for ≥ 6
- Pregnant or lactating,
months
alcohol/drug abuse
Becker
et al.
(2007)5

Double
blind
RCT

84

≥29

Yang et
al.
(2008)6

Double
blind
RCT

182

≥18

- Unilateral
lumbar radicular
compression
- Clinical dx
confirmed by
MRI or CT
showing
herniation
- Pain duration
must be 6
weeks≥
- Clinical
evidence of OA
- Knee
complaints
surpassing the
threshold
indicated on
WOMAC,
KOOS, or VAS

W/D

Interventions

31

Intraarticular
injections of
autologous IL-I
receptor
antagonist vs.
HA once/wk x
3 weeks

- Pts needing early
surgery b/c of paresis or
unbearable pain
- Neurological illness
- Cervical myopathy
- Systemic bone or joint
illness
- Cortisone or opiod use
in the last 6 months

1

- Overall poor general
health
- Suspicion of ipsilateral
coxarthrosis and hip
prosthesis loosening
- Alcohol/drug abuse
- OA grade IV
- Known
immunodeficiency
- Known coagulopathy
- Corticosteroid and anticoagulant usage or
morbid obesity

9

Autologous
epidural
perineural
interleukin-1
receptor
antagonist
injection vs 5
or 10 mg
triamcinolone
once/wk x 3
weeks
Intraarticular
injections of
autologous IL-I
receptor
antagonist vs
placebo on
days 0, 3, 7, 10,
14, and 21.

Outcomes measured:
The outcomes in this study were measured using the Western Ontario and McMaster
Osteoarthritis Index (WOMAC), Knee Injury and Osteoarthritis Outcome Score (KOOS), Visual
Analogue Scale (VAS), and the Oswestry Disability Index (ODI). The WOMAC is comprised of
24 items subdivided into 3 categories: Pain, stiffness, and physical function.9 The KOOS, on the
other hand, consists of 5 different categories: Pain, other symptoms (such as a grinding sensation
or knee ‘clicking’), function in daily living, function in sports and recreation, and knee related
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quality of life. These 5 categories are added to give a value of 0-100, with 100 indicating no
symptoms. The VAS simply measures a patients pain level on a scale from 0-100, with 100
being the highest possible pain. The final analysis modality, the ODI, assesses how much an
individual is affected by lower back pain via 10 criteria and scaled from 0-100%, with 0% being
minimal interference with daily life and 100% being completely bedbound.10 The WOMAC,
KOOS, and ODI are determined by questionnaires filled out by patients, while all 4 analytical
modalities are subjective and thus subject to variability and human error.
Results:
The Yang et al. study included 167 patients, with 89 receiving the ACS treatment,
while78 received the placebo. Of the 167 patients that received an injection, 80 and 74 patients
completed the study for the experimental and control arms, respectively; both accounting for an
84% retention rate. Follow-up duration was 12 months, with patient reporting every 3 months.
Both the treatment and control arms exhibited a significant improvement in all analytical
modalities when compared to baseline (P<.001). The only statistically significant improvements
seen in ACS-treated group versus the placebo group was in the KOOS Symptomology (P =
0.002) and KOOS Sport (P = 0.042). These data points were continuous and summarized in a
graph and thus unable to be obtained for analysis. The differences in pain reduction between the
experimental and control arms on the VAS was not statistically significant and can be seen in
Table 2 below. The most significant adverse event was knee irritation following injection
(orthokine = 70 vs. placebo = 67). The NNH could not be calculated because this was not
dichotomous data.8
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Table 2: VAS results for ACS-treated patients versus placebo.
Orthokine
Baseline
3 months
6 months
9 months
12 months
Placebo
Baseline
3 months
6 months
9 months
12 months

VAS, mean
59.68
43.63
48.59
48.91
47.32
VAS, mean
63.44
47.51
49.06
50.79
49.76

SD
20.2
26.5
28.5
27.7
28.0
SD
18.2
26.5
27.4
25.4
26.7

The Baltzer et al. study 376 patients who underwent at least one intraarticular injection.
Of those 376 patients, 134 were treated with ACS, 135 with HA, and 107 with saline. The
number of patients who completed the trial were 126 (94%), 120 (89%), and 99 (93%) for the
ACS, HA, and saline groups, respectively. Follow up duration was 26 weeks, with patients
reporting on weeks 7, 13, and 16. All results for pain in the WOMAC and VAS analysis were
statistically significant for the ACS-treated group when compared to the control groups (Table 3).
Furthermore, there were no statistically significant differences appreciated between the HA and
saline groups for any of the WOMAC scores (P>.05). Adverse events were seen in 23%, 38%,
and 28% of the ACS, HA, and saline-treated groups, respectively. The main ADR for all groups
was localized pain and irritation and accounted for 79% of the total amount of all ADR’s. Again,
the NNH could not be calculated because this was not dichotomous data.6
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Table 3: Statistically significant effects for pain in the ACS-treated group versus controls.
Results determined from last visit minus baseline.
Variable
P-value
Comparison
Significance
WOMACpain
.001
ACS-Saline
Yes
ACS-HA
Yes
HA-Saline
No
VAS

.001

ACS-Saline
ACS-HA
HA-Saline

Yes
Yes
No

The Becker et al. study was comprised of 84 patients, with 32, 27, and 25 patients being
treated with ACS, 5 mg triamcinolone, and 10 mg triamcinolone, respectively. It is not clear how
many patients from each group finished the trial. Follow up duration was 22 weeks, with patients
reporting at 6, 10, and 22 weeks. It was found that all treatment modalities exhibited statistically
significant changes from baseline in both the VAS and ODI at all time points. At the end of the
study, the ACS group showed a statistically significant difference when compared to the 5 mg,
but not the 10 mg, triamcinolone group (P<0.046). There was a total of 1 ADR for each group,
which was a headache at the time of injection.

Discussion:
The main purpose of this meta-analysis was to determine if ACS reduced pain in patients
with OA and LR. A careful review of the data presented shows conflicting results for OA. In the
Yang et al. study, pain was not significantly reduced in the experimental group when compared
to the control group; in fact, the control group performed almost just as well as the experimental
group when NSAID’s were discontinued. This was a unique and unexpected result, as one would
not expect the cessation of NSAID’s to decrease pain in the following months. Though there is
no literature to support NSAID-induced hyperalgesia, the medical community is replete with
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studies on the effects of opiod-induced hypersalgesia. A future study comparing NSAID-induced
hyperalgesia versus opiod-induced hyperalgesia would be a valuable tool to either confirm or
refute this theory.13
On the other hand, data from the Baltzer et al. trial is highly convincing of the benefit
ACS intraarticular injections have on pain when compared to HA and placebo. For the entire
duration of the trial, ACS-treated patients faired significantly better on both the VAS and
WOMACpain scale when compared to the other 2 treatment modalities. It should be noted that in
this study patients were forced to discontinue the use of analgesics 3 weeks prior to the
commencement and up until the end of the trial. Again, one has to wonder about the possibility
of NSAID-induced hyperalgesia. It should also be noted that there were some methodological
differences between the two studies. Baltzer et al. utilized 6 intraarticular injections over a 3
week period, while Yang et al. performed only 3 injections over the same time period.
The Becker et al. study analyzing the effects of ACS versus triamcinolone injections for
LR failed to show statistically significant benefits overall. It appeared that 10 mg of
triamcinolone was just as effective as ACS. As a result, treatment with ACS does not appear to
be cost-effective when compared to triamcinolone ($7400 vs. $1850 per injection).14,15 It is also
important to note that ACS is considered an experimental therapy and is thus not covered by
medical insurance.
Limitations were present for each study and may have affected the clinical outcomes. All
3 trials had small patient populations, ranging from 376 to 84. Such a small sample size can skew
data, as outliers often impart a greater impact on results. This was even noted in the Becker et al.
trial, where the mean and median figures for the experimental group were markedly different,
leading to skewed data. Furthermore, the studies utilized subjective tools to measure patient pain,
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rendering them liable to patient bias. The patient population was also highly variable, as there are
different grades of OA. It is possible that certain grades are more responsive to treatment than
others.

Conclusion:
ACS does appear to decrease pain in patients with OA and LR; however, evidence is not
conclusive as to how effective the treatment is versus other modalities. As a result, further
research is warranted prior to determining the cost-effectiveness of this therapy, especially when
considering it is not yet an approved therapy in the US and thus not covered by health insurance.
Future studies should attempt to replicate that of the Baltzer et al. trial, as that appeared to have
the most success in ameliorating pain. Furthermore, a study elucidating the most effective
schedule for intraarticular injections would be recommended prior to implementation of this
strategy.
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